Preclinical Assessment of mRNA Vaccines using LNP Delivery Systems in Infectious Disease Models

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Preclinical Assessment of mRNA Vaccines using LNP Delivery Systems in Infectious Disease Models

Preclinical Efficacy Models for LNP-Delivered mRNA Vaccines

CELL & GENE | RNA | BIOLOGICS

  • De-risking LNP-mRNA constructs through predictive in vivo modeling.*

Successful development of lipid nanoparticle (LNP) delivered mRNA vaccines requires a robust preclinical data package that validates formulation stability, delivery efficiency, and protective immunogenicity. Franklin Biolabs executes comprehensive pharmacology and efficacy studies in well-characterized infectious disease models. We generate decision-driving data on antigen expression, neutralizing antibody titers, T-cell responses, and post-challenge protection to support an accelerated 18-24 month IND timeline.

    What are the key readouts in an LNP-mRNA vaccine efficacy study?

    A: Core endpoints include quantification of antigen expression in target tissues, assessment of immunogenicity via neutralizing antibody titers and T-cell activation profiles (ELISpot/Flow Cytometry), and evaluation of protective efficacy through survival and viral load reduction in challenge models.

    How do you assess the stability and delivery efficiency of the LNP formulation in vivo?

    A: We determine the in vivo fate of the construct through non-target tissue biodistribution studies using labeled LNPs or mRNA. This is correlated with functional readouts, such as quantifying protein expression in target tissues like muscle or lymph nodes to confirm successful payload delivery and translation.

    How does Franklin Biolabs ensure consistent LNP production for preclinical studies?

    A: We collaborate with strategic manufacturing partners who employ scalable production methodologies. This focus on process control ensures the preclinical test article is representative of the eventual clinical candidate, as manufacturing methods are known to impact in vivo potency.

    What is your regulatory track record for programs involving complex biologics?

    A: Since 2019, programs we have supported have achieved a 100% IND success rate. The Franklin Biolabs brand, which unifies these services, launched in 2024, continuing this legacy of regulatory excellence from within our >100,000 sq ft facility.

Characterizing LNP Delivery and Payload Expression

The efficacy of an mRNA vaccine is directly dependent on the LNP vehicle’s ability to protect its payload and deliver it to the appropriate cellular machinery. Before entering challenge studies, we establish a baseline of performance for the formulation itself.

Our programs are designed to answer fundamental questions about the construct’s behavior in a biological system.

  • Biodistribution: We map the disposition of the LNP and its mRNA cargo to confirm delivery to target immune sites and identify potential accumulation in non-target tissues.

  • Protein Expression: We quantify the magnitude and duration of antigen expression in vivo, providing a mechanistic link between dose, delivery, and the initiation of an immune response.

This integrated analysis of biodistribution and protein expression provides the high-resolution pharmacology validating complex biologicals and establishing a clear link between dose and initial biological activity.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Quantifying Immunogenicity and Protective Efficacy

The primary objective of a vaccine efficacy study is to measure the resulting immune response and its ability to protect against a pathogenic challenge. We employ a suite of assays to build a comprehensive immunogenicity profile.

Key functional endpoints include:

  • Humoral Immunity: Measurement of binding and neutralizing antibody titers.

  • Cellular Immunity: Characterization of antigen-specific T-cell responses.

  • Challenge Model Performance: Assessment of clinical signs, body weight changes, and pathogen burden in tissues following a live virus challenge.

Strategic Considerations for Clinical Translation

Preclinical data must be viewed through the lens of regulatory submission and clinical scalability. Our study designs incorporate these considerations from the outset. Scientific literature shows that LNP-mRNA platforms can offer mutation-independent therapeutic strategies (PMID: 39001827), highlighting the importance of designing preclinical models that can demonstrate broad applicability.

Understanding how manufacturing variables influence in vivo potency is a key development insight (PMID: 34189917). By characterizing test articles thoroughly, we help de-risk the technical transfer and scale-up activities that run parallel to IND-enabling safety studies.

A blue-toned image of white lab rats in their cages within a laboratory or vivarium setting, likely for scientific research or testing.

Commitment to Animal Welfare

Our animal care and use program is USDA registered, and we conduct studies in AAALAC-accredited facilities. All study designs incorporate the 3Rs (Replacement, Reduction, and Refinement) to ensure responsible and ethical research practices.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities